The initial discovery that ras genes endowed retroviruses with potent carcinogenic properties and the subsequent determination that mutated ras genes were present in a wide variety of human cancers, prompted a strong suspicion that the growth-promoting actions of mutated Ras proteins contribute to their aberrant regulation of growth stimulatory signaling pathways. In 1993, a remarkable convergence of experimental observations from genetic analyses of Drosophila, S. cerevisiae and C. elegans as well as biochemical and biological studies in mammalian cells came together to de®ne a clear role for Ras in signal transduction. What emerged was an elegant linear signaling pathway where Ras functions as a relay switch that is positioned downstream of cell surface receptor tyrosine kinases and upstream of a cytoplasmic cascade of kinases that included the mitogen-activated protein kinases (MAPKs). Activated MAPKs in turn regulated the activities of nuclear transcription factors. Thus, a signaling cascade where every component between the cell surface and the nucleus was de®ned and conserved in worms,¯ies and man. This was a remarkable achievement in our eorts to appreciate how the aberrant function of Ras proteins may contribute to the malignant growth properties of the cancer cell. However, the identi®cation of this pathway has proven to be just the beginning, rather than the culmination, of our understanding of Ras in signal transduction. Instead, we now appreciate that this simple linear pathway represents but a minor component of a very complex signaling circuitry. Ras signaling has emerged to involve a complex array of signaling pathways, where cross-talk, feedback loops, branch points and multi-component signaling complexes are recurring themes. The simplest concept of a signaling cascade, where each component simply relays the same message to the next, is clearly not the case. In this review, we summarize our current understanding of Ras signal transduction with an emphasis on new complexities associated with the recognition and/or activation of cellular eectors, and the diverse array of signaling pathways mediated by interaction between Ras and Ras-subfamily proteins with multiple eectors.
Introduction
This review will summarize three major emerging themes that have refocused our perceptions on how Ras functions in signal transduction. First, it has become clear that the role of Ras in recognition and activation of one its downstream targets, the Raf-1 serine/threonine kinase, is much more complex than originally envisioned. Earlier studies suggested that the primary role of Ras was to localize Raf-1 to the membrane where other factors were involved in the activation of Raf-1 kinase activity. However, more recent data suggests that Raf-1 activation is a complex multi-step process, where Ras is involved in the initial stages of activation, and possesses a direct role in both membrane localization and activation of Raf-1. The recognition and pre-activation of Raf-1 by Ras appears to be accomplished through binding interactions between multiple sites in Ras and at least two distinct domains of Raf-1. Second, the Raf-1 serine/threonine kinase is not the sole downstream eector of Ras. Earlier proclamations that Ras served simply as an activator of Raf-1 were clearly premature. Instead, what has emerged is that Ras utilizes a multitude of functionally diverse eector targets which are likely to transduce signals through multiple pathways. Third, the Ras subfamily consists of an expanding group of GTPases that show high homology to Ras yet display distinct signaling properties. This, most likely re¯ects the dierential interaction between these Ras-related proteins and additional cellular factors, regulators and eectors.
Targeting components of the Ras signaling pathways has been proposed as one approach for the development of anti-Ras drugs for cancer treatment. The realization that our comprehension of the complexities of Ras signaling is quite limited, and simple-minded, may discourage any serious consideration that this is a fruitful direction for drug discovery at this time. Thus, there are some who are of the opinion that such eorts are premature and must await a complete knowledge of this signaling circuitry. However, evidence that intervention of Ras signaling at multiple points can signi®cantly impact the ability of Ras to cause cellular transformation, argues that a full unveiling of all the complexities of Ras signaling will not be required before successful targeting of Ras signaling pathways for drug discovery can be achieved.
Ras is a point of convergence for diverse extracellular signal-stimulated pathways function as GDP/GTP regulated switches (H-Ras, NRas, K-Ras4A and K-Ras4B) (Barbacid, 1987; Bourne et al., 1990; Boguski and McCormick, 1993; Quilliam et al., 1995) . The two forms of K-Ras diverge solely in their COOH-terminal 25 amino acids as a consequence of alternate exon utilization. Ras proteins are positioned at the inner surface of the plasma membrane where they serve as binary molecular switches to transduce extracellular ligand-mediated stimuli into the cytoplasm to control signal transduction pathways that in¯uence cell growth, dierentiation and apoptosis (Satoh and Kaziro, 1992; Khosravi-Far and Der, 1994) . Ras biological activity is controlled by a regulated GDP/GTP cycle (Figure 1 ). The intrinsic GDP/GTP exchange and GTP hydrolytic activity of Ras is very low and hence, cellular control of GDP/ GTP cycling modulated by two types of regulatory proteins. Guanine nucleotide exchange factors (GEFs; RasGRF/mCDC25, SOS1/2) promote formation of the active GTP-bound state and Ras GTPase activating proteins (GAPs; p120 GAP, NF1-GAP/neuro®bromin) promote formation of the inactive GDP-bound state (Boguski and McCormick, 1993; Quilliam et al., 1995) . The single amino acid substitutions at 12, 13 or 61 that unmask Ras transforming potential create mutant proteins that are insensitive to GAP stimulation (Bos, 1989; . Consequently, these oncogenic Ras mutant proteins are locked in the active, GTP-bound state, leading to constitutive, deregulated activation of Ras function.
Ras activation of the Raf4MEK4MAPK kinase cascade. Ras is a point of convergence for many signaling pathways (Khosravi-Far and Der, 1994) . Ras proteins are activated transiently in response to a diverse array of extracellular signals such as growth factors, cytokines, hormones and neurotransmitters that stimulate cell surface receptors and include receptor tyrosine kinases (RTKs), non-receptor tyrosine kinase-associated receptors, and G proteincoupled seven transmembrane receptors (SRs) (Satoh and Kaziro, 1992; Khosravi-Far and Der, 1994) . The best characterized Ras-mediated signal transduction pathway involves the activation of peptide mitogenstimulated RTKs such as the epidermal growth factor (EGF) receptor (EGFR) (Figure 1 ) (Egan and Weinberg, 1993; Khosravi-Far and Der, 1994) . The EGF-stimulated EGFR undergoes autophosphorylation of speci®c tyrosine residues in its cytoplasmic domain which creates phosphotyrosyl binding sites for the Src homology 2 (SH2) and/or phosphotyrosyl binding (PTB) domains of the Shc and/or Grb2 adaptor proteins (Williams, 1992; Mayer and Baltimore, 1993; Schlessinger, 1993b) . Shc becomes autophosphorylated on association with activated RTKs which creates recognition sites for the SH 2 domain of Grb2. Since Grb2 is stably associated with SOS, the Shc/Grb2-or Grb2-mediated translocation of the Ras GEF SOS to the plasma membrane, where Ras resides, leads to the transient elevation of Ras-GTP levels (Feig, 1994; Schlessinger, 1993a) . Shc, Grb2 and SOS provide the link between many types of activated cell surface receptors and Ras (Williams, 1992; Schlessinger, 1993b) .
Activated Ras relays its signal downstream through a cascade of cytoplasmic proteins (Figure 1 ). Substantial biological, biochemical and genetic evidence has implicated the Raf-1 serine/threonine kinase as a critical eector of Ras function (Moodie and Wolfman, 1994) . A key observation was that biologically active, but not inactive, Ras forms a high anity complex with Raf-1 (Van Aelst et al., 1993; Moodie et al., 1993; Zhang et al., 1993; Warne et al., 1993; Vojtek et al., 1993) . The Ras:Raf association promotes a translocation of the normally cytoplasmic Raf protein to the plasma membrane, where subsequent events lead to the activation of its kinase function. These events are complex and remain to be fully understood (Morrison and Cutler, 1997) , as will be discussed in more detail below. Upon activation, Raf then phosphorylates and activates two MAPK kinases (MAPKKs; also called MEK1 and MEK2). MEKs directly associate with the COOH-terminal catalytic domain of Raf-1 and are phosphorylated by Raf (Crews and Erikson, 1993) . Activated MEKs function as dual speci®city kinases, and phosphorylate tandem threonine and tyrosine residues (TEY motif) in two MAPKs (also referred to as extracellular signal regulated kinases; ERKs), designated p42 MAPK /Erk2 and p44 MAPK /Erk1 to activate them (Crews et al., 1992) . Once activated MAPKs translocate to the nucleus where they phosphorylate and activate a variety of substrates that include the Elk-1 nuclear transcription factor (Marais et al., 1993) . Elk-1 forms a complex with serum response factor (SRF) at the serum response DNA element (SRE) present in many promoters such as the c-fos promoter (Treisman, 1996b) . MAPKs also activate other kinases, Figure 1 Ras regulation of a cascade of kinases. Ras serves as a GDP/GTP-related binary switch that resides at the inner surface of the plasma membrane and acts as a relay for extracellular ligand-stimulated signals to cytoplasmic signaling cascades. A linear pathway where Ras functions downstream of receptor tyrosine kinases (RTKs, such as the EGFR receptor) and upstream of a cascade of serine/threonine kinases (Raf4MEK4MAPK) provides a complete link between the cell surface and the nucleus such as the p90 RSK serine/threonine kinase, to regulate protein synthesis (Blenis, 1993) .
Much of the information that has allowed the delineation of this Ras signaling pathway has come from genetic studies of the fruit¯y Drosophila melanogaster, the nematode Caenorhabditis elegans, the baker's yeast Saccharomyces cerevisiae and the ®ssion yeast Schizosaccharomyces pombe. Drosophila eye development is controlled by a signaling pathway that begins with ligand stimulation of the Sevenless RTK, leading to the activation of a Ras homolog, which in turn activates a MAPK cascade (Rubin, 1991) . A near-identical scheme is seen for the pathway that regulates proper development of the vulva in C. elegans, which involves a RTK (Let-23)-mediated pathway that activates the Ras homolog, Let-60 (Sternberg and Horvitz, 1991) . S. pombe Ras1 also activates a MAPK cascade (Nishida and Gotoh, 1993) . In fact, much of the early clues that identi®ed the positive (CDC25) and negative (IRA) regulators of Ras GDP/GTP cycling came from RAS studies in S. cerevisiae (reviewed in Tamanoi, 1988; Broach, 1991 (Kolch et al., 1991; Schaap et al., 1993; Cowley et al., 1994; Westwick et al., 1994; Qiu et al., 1995a; Khosravi-Far et al., 1995) . Similarly, loss of function mutations in Raf, MEK or MAPK homologs disrupt these Rasmediated developmental pathways in¯ies and worms (reviewed in Satoh and Kaziro, 1992) . Conversely, constitutively activated mutants of Raf-1 cause a transformed and tumorigenic phenotype which is indistinguishable from that caused by oncogenic mutants of Ras, when analysed in rodent ®broblast transformation assays (Bonner et al., 1985; Stanton, et al., 1989; Leevers et al., 1994; Stokoe et al., 1994) . Constitutively activated mutants of MEK also cause morphologic and growth transformation of NIH3T3 cells (Alessi et al., 1994; Mansour et al., 1994) . Gain of function mutations in homologs of Raf, MEK or MAPK can overcome the loss of Ras function in the fruit¯y and nematode (Dickson et al., 1992; Sprenger et al., 1993) . Constitutively activated Raf-1 can overcome the loss of Ras function caused by dominant negative mutants of Ras (e.g., Ras(17N)) or by the Y13-259 anti-Ras neutralizing monoclonal antibody (Smith et al., 1986; Feig and Cooper, 1988) . Finally, when it was demonstrated that targeting Raf-1 to the plasma membrane alone was sucient to fully unmask its transforming activity (Leevers et al., 1994; Stokoe et al., 1994) , it was suggested that the biochemical function of Ras was simply to promote the membrane association and activation of Raf-1. When taken together, these observations supported the likelihood that the Raf4MEK4MAPK cascade was both necessary and sucient for Ras function.
Ras-mediated activation of Raf-1 As detailed above, a large body of evidence supports the role of Ras in mediating activation of Raf. However, the interaction of Ras and Raf-1 in vitro is insucient to stimulate Raf-1 kinase activity, (Traverse et al., 1993; indicating that in addition to Ras, other factors are required for Raf-1 activation in vivo. Initial reports suggested that Ras bound to Raf-1 at a single site (Pumiglia et al., 1995) and served simply to translocate Raf-1 to the plasma membrane (Stokoe et al., 1994; Leevers et al., 1994) . However, the ability of a membrane-free complex of B-Raf and 14-3-3 proteins to be activated in vitro by Ras suggests that Ras may play a direct role in Raf activation . Furthermore, the identi®cation of Ras mutants that bind to Raf-1 with high anity but are defective in Raf-1 activation, suggested that a direct correlation could not be made between the anity of Raf-1 to Ras-GTP and Raf-1 activation, as would be expected if the sole role of Ras in Raf activation is its recruitment to the membrane (Akasaka et al., 1996) . Hence these observations, coupled with recent ®ndings that Ras interacts with two distinct NH 2 -terminal regions of Raf-1, suggests that Ras promotes more than just membrane translocation of Raf, and instead, may also facilitate subsequent events that lead to Raf-1 activation ( Figure 2 ) (Brtva et al., 1995; Drugan et al., 1996; . The prevailing data indicate that the ®rst Ras binding site (RBS) in Raf-1 (residues 55 ± 131) is required for Raf-1 translocation by Ras, whereas interactions between processed Ras and the second Ras binding site in the cysteine-rich domain (CRD) of Raf-1 are required for full activation of Raf-1 activity by Ras (Roy et al., 1997; Clark et al., 1995; Mineo et al., 1997) . Other components that may contribute to Raf-1 activation include the Hsp90 and p50 molecular chaperones, phospholipids, serine/ threonine and tyrosine kinases, and the kinase suppressor of Ras (KSR) (reviewed in Morrison and Cutler, 1997) .
A further level of regulation involves the interaction of Raf-1 with 14-3-3 proteins. This family of ubiquitously expressed, highly conserved proteins can exist as dimers and are known to complex with a variety of proteins (BCR, cdc25, A20, PKC) suggesting that they may act as an adaptor proteins (Braselmann and McCormick, 1995; Conklin et al., 1995; Vincenz and Dixit, 1996) . The role of 14-3-3 in Raf-1 regulation remains controversial (Michaud et al., 1995; Suen et al., 1995; Li et al., 1995; Irie et al., 1994; Freed et al., 1994; Fantl et al., 1994; Chang and Rubin, 1997; Luo et al., 1996; Braselmann and McCormick, 1995; Shimizu et al., 1994) . This may be due, at least in part, to the complex nature of the Raf-1/14-3-3 interaction which involves multiple binding sites, including the Raf-1 CRD and two sites containing a phospho-serine consensus sequence for 14-3-3 at positions 259 and 621 of Raf-1 (Clark et al., 1997b; Li et al., 1993) . Moreover, the heterogeneity of the 14-3-3 family and the ability of these proteins to form dimers and heterodimers complicates the interpretation of their role in Raf-1 regulation. We and others (Rommel et al., 1996 Clark et al., 1997b) have recently proposed a dual role for 14-3-3 in Raf-1 regulation, with 14-3-3 proteins either stimulating or inhibiting as appropriate by binding to dierent sites on Raf-1. Recent data using Raf-1 mutants which selectively disrupt 14-3-3 binding sites on Raf-1 appear to support this latter hypothesis Clark et al., 1997b ).
Yet another level of complexity was added to the regulation of Raf-1 when it was demonstrated that the cysteine-rich domain (CRD) of Raf-1 binds to the anionic membrane phospholipid, phosphatidylserine (PS) (Ghosh et al., 1994) . Moreover, it has now been demonstrated that the addition of PS to a cellular preparation of K-Ras and B-Raf enhances the activation of B-Raf and that the addition of a mixture of plasma membrane lipid comonents, including PS, allows Ras to activate c-Raf-1 in vitro (Stokoe and McCormick, 1997) . We have recently generated Raf-1 CRD variants which are speci®cally impaired for binding of PS (Clark et al., 1997a) , and found them to be defective in Raf-1 activation. However, the interaction with PS becomes unnecessary for the activation of Raf-1 in CRD mutants which are defective in both PS and 14-3-3 binding. Furthermore, we have found that the binding sites for 14-3-3 and PS in the Raf-1 CRD appear to overlap, and that PS can compete with 14-3-3 for binding to the CRD of Raf-1. Thus, a model is presented in Figure 2 where the activation of Raf-1 by Ras involves recruitment to the plasma membrane via binding to the ®rst Ras binding site (RBS) of a Raf-1 molecule constitutively associated with 14-3-3 (Rommel et al., 1996) . Once at the plasma membrane, PS acts to promote the interaction of Ras and the second Ras binding site of Raf-1 (CRD) by displacing 14-3-3 to permit full Raf-1 activation by other factors such as KSR, HSP90, and both serine/ threonine and tyrosine kinases (as reviewed in Morrison and Cutler, 1997) . Therefore, the connection between Ras and Raf-1 alone is not simply linear and appears to be a multi-step activation process requiring multi-complex formation to complete Raf activation. As will be discussed, this theme of Ras-mediated multistep eector activation and eector-mediated multicomplex formation may be extended also to other Ras eectors. In other words, the complexities we are just now delineating in the recognition of Ras by Raf and its role in Raf-1 activation, may serve as a prototype for the interaction and activation of other eectors by Ras and Ras-related proteins.
Other observations also revealed the oversimplification of a Raf4MEK4MAPK linear cascade. For example, the mammalian Raf protein family contains three family members: Raf-1, A-Raf and B-Raf, with B-Raf existing in multiple spliced forms Eychene et al., 1995) . Recent data indicate that unique regulatory events are likely to be involved in the activation of each of the three family members. For example, it has been shown previously that maximal activation of Raf-1 is produced by synergistic signals from oncogenic Ras and activated tyrosine kinases (Marais et al., 1995) . In particular, A-Raf like Raf-1, appears to be weakly activated by oncogenic Ras and more strongly activated by oncogenic Src, and these signals synergize to give maximal activation. In contrast, B-Raf is strongly activated by oncogenic Ras alone and is not activated by oncogenic Src (Marais et al., 1997) . Similarly, protein kinase C (PKC) can phosphorylate and activate Raf-1 directly (Morrison, 1994; Sozeri et al., 1992; Kolch et al., 1993) , whereas protein kinase A antagonizes EGFactivated MAPK signaling pathway (Wu et al., 1993) . The supporting data, although controversial, suggests that MAPK inhibition by PKA results from phosphorylation and inhibition of Figure 2 Ras-mediated activation of Raf is a complex multi-step process. Although Ras-GTP activation of Raf is mediated by causing the translocation of Raf from the cytosol to the inner surface of the plasma membrane, other events are required to activate Raf kinase function. Ras, via interaction with a second distinct binding site in the cysteine-rich domain of Raf (CRD), may also promote other events that allow the subsequent activation steps to occur. 14-3-3 interacts with multiple regions of Raf and may serve as a negative regulator. Other possible components that may be involved in Raf activation include KSR, phosphatidylserine, p50 and Hsp90, and both tyrosine and serine/threonine kinases. The requirement for multiple signals to activate Raf-1 underscores an emerging theme that eectors may promote complex formation at the level of Ras, rather than simply forming a linear signaling pathway Raf-1 activity (Chuang et al., 1994; Weissinger et al., 1997) .
MAPKs can be activated by Ras-independent mechanisms. For example, the activation of MEK and ERK by an activated form of PKCd requires the presence of c-Raf and is independent of a dominant negative form of Ras (RasN17) . In addition, evidence for P13K and cPKCs mediated MEK-independent activation of MAPK exists (Grammer and Blenis, 1997) . Moreover, integrin-mediated activation of MAPKs can occur by a process independent of Ras (Chen et al., 1996a) . However, MEK transforming activity may still be dependent on Ras function . Furthermore, MAPKs can phosphorylate MEK, although the functional consequences are not clear. Raf and MEK can cause activation of the p70 S6 kinase, but apparently independent of p42/p44 MAPK activation (Lenormand et al., 1996) . Finally, MEK1 has been shown to mediate activation of Raf-1 by a novel positive feedback mechanism that is independent of Ras, Src and tyrosine phosphorylation of Raf-1 (Zimmermann et al., 1997) . In particular, MEK has been shown to phosphorylate both the amino-and carboxyl terminus of Raf-1. Only phosphorylation of the carboxyl terminal catalytic domain of Raf-1 appears to correlate with increased Raf-1 kinase activity. Taken together, each signaling protein in this cascade is likely to have additional targets and each component may be activated by other upstream components. Furthermore, feedback loops and autocrine mechanisms may also exist. For example, Raf activation of a second MAPK pathway, involving the Jun NH 2 -terminal kinase (JNK; also known as SAPK) was found to be mediated by an autocrine loop involving the EGF receptor (Minden et al., 1994) . Hence, this signaling cascade is not a simple linear pathway. Various stimuli and cell types are likely to dierentially utilize multiple, possibly temporally distinct pathways converging on MAPK. Moreover, recent observations began to establish that Raf is not the sole downstream target of Ras and that Ras function may require its association with a surprisingly large number of other eectors, leading to transduction of Ras-mediated signals through multiple pathways (Boguski and McCormick, 1993) Ras activation of Raf-independent pathways contribute to Ras transformation Despite the apparent linear nature of the Ras4Raf4MEK4MAPK signaling cascade, there was also mounting evidence that it represented but a mere subset of a very complex array of signaling interactions at several levels. For example, a considerable body of evidence supports the hypothesis that Raf is not the sole eector of Ras function and that Rafindependent pathways are critical for mediating Ras function. First, genetics studies in S. pombe revealed the involvement of at least two distinct downstream eector-mediated signaling pathways that facilitate full Ras1 function (Marcus et al., 1995) . One eector of Ras1 is Byr2, a MEKK/Raf homolog (Van Aelst et al., 1993; Wang et al., 1991) . Byr2 is a component of a protein kinase cascade that includes Byr1 (MEK) and Spk1 (MAPK) that regulates agglutination, conjugation and sporulation. Like Raf, Byr2 has a distinctive N-terminal kinase regulatory domain and a characteristic C-terminal kinase catalytic domain, where multiple protein interactions within the regulatory domain appear to be required for control of Byr2 kinase activity (Tu et al., 1997) . Scd1 represents a second eector and functions as an exchange factor for the S. pombe CDC42 homolog, Cdc42 (Chang et al., 1994) . Scd1 regulates a pathway that includes CDC42 and Shk1 (PAK homolog) and controls cell morphology (Marcus et al., 1995) . Hence, these data provide a link between Ras and Rho family proteins and de®ne two distinct Ras1 eector mediated activities. Whether a speci®c mammalian Rho GEF(s), analogous to Scd1, can function as a Ras eector remains to be determined. Finally, although the best characterized eector of S. cerevisiae RAS2 is not a Raf-related molecule, and is instead adenylate cyclase, a second Ras-dependent pathway was suggested by the fact that loss of RAS, but not adenylate cyclase, is lethal (Toda et al., 1985) . RAS2 also signals via a CDC42/STE20 MAPK cascade to induce ®lamentous growth (MoÈ sch et al., 1996) .
Second, in addition to p42 and p44 MAPKs/ ERKs, activated Ras induces activation of the JNK/ SAPK and p38/HOG MAPK cascades, which in turn activate the Elk-1, c-Jun and ATF-2 nuclear transcription factors (DeÂ rijard et al., 1994) . While these kinase cascades are analogous to the Raf4MEK4MAPK cascade (reviewed in Treisman, 1996a; Kyriakis and Avruch, 1996) they de®ne parallel pathways that are stimulated independent of Raf activation (Minden et al., 1994; Olson et al., 1995) . However, whereas ERK activation is associated with growth stimulatory responses, JNK and p38 activation are typically associated with stress responses that result in apoptosis (Xia et al., 1995; Verheij et al., 1996; Chen et al., 1996b) . For example, MEKK1 activates both JNK and p38 and causes apoptosis . Similarly, activation of JNKs is associated with apoptosis in PC12 pheochromocytoma, U937 leukemia and other cell types (Xia et al., 1995; Verheij et al., 1996; Chen et al., 1996b) . However, we recently observed that inhibition of JNK activation impaired Ras transformation suggesting a growth promoting role for this MAPK cascade (Clark et al., 1997d) . Jun function is also required for Ras transformation (GrangerSchnarr et al., 1992; Clark et al., 1997d) . Therefore, JNK activation may promote dierent cellular consequences that depend on the coordinate activation of other pathways. Thus, JNK activation by stress stimuli alone may cause apoptosis, whereas JNK activation under other conditions may synergistically enhance the growth promoting action of activated MAPKs (Xia et al., 1995) . Alternatively, JNK activation may possess cell type speci®c actions (DeÂ rijard et al., 1994; Xia et al., 1995; Verheij et al., 1996; Chen et al., 1996b; Su et al., 1994) , and serve a protective function, at least in ®broblasts, and thereby contribute to cell transformation.
Third, transformation studies in several epithelial cell lines including RIE-1 rat intestinal epithelial cells, showed that Ras activation of the Raf4MEK4MAPK pathway alone was not sufficient to cause complete transformation (Oldham et al., 1996) . Whereas constitutively activated mutants of Ras and Raf-1 show equivalent transforming potencies when assayed in rodent ®broblast transformation analyses, activated Raf failed to cause morphologic and growth transformation of RIE-1 cells. Instead, Ras activation of Raf-independent pathways, which led to the induction of an EGFR-dependent autocrine growth pathway, was found to be critical for oncogenic Ras transformation of these cells (Gangarosa et al., 1997) . Other evidence for the inability of Raf to promote full Ras function was provided by a study that showed that Ras, but not Raf, could trigger the morphologic changes and actin reorganization associated with cellular hypertrophy (Thorburn et al., 1993) .
Fourth, it has been shown that constitutively activated mutants of two members of the Ras branch of Ras-related proteins (TC21/R-Ras2 and R-Ras; 55% identity with Ras) can cause tumorigenic transformation of rodent ®broblasts ( Figure 3 ) (Graham et al., 1994; Chan et al., 1994; Saez et al., 1994; Cox et al., 1994) . Although both TC21 and RRas share complete sequence identity with the core Ras eector domain (residues 32 ± 40), as shown in Figure  4 , and can interact with an isolated Ras-binding domain present in the NH 2 -terminus of Raf-1, these proteins failed to interact with and activate Raf kinases in vivo or to directly activate ERKs (Graham et al., 1996; Hu et al., 1997) . In particular, we have found that activated TC21 exhibits the same dierentiationinducing (PC12 cells) or dierentiation-inhibiting (C2 myoblasts) phenotype that has been observed with activated Ras (Graham and Der, unpublished observations) . Therefore, Raf-independent pathways are clearly sucient to mediate the transforming and dierentiating functions of TC21 and, presumably, Ras. While the Raf-independent pathways that promote transformation by these two Ras-related proteins are presently not known, it is suspected that Ras may activate some of these Raf-independent pathways. This hypothesis is based in part on the fact that TC21 and R-Ras can interact with many of the Ras-GTP binding partners that have been identi®ed.
Finally, important and direct evidence for the involvement of multiple signaling pathways downstream of Ras comes from the identi®cation of Ras eector domain mutants that are defective in interaction and activation of Raf . These Raf-binding defective mutants, designated Ras(12V, 37G) and Ras(12V, 40C), no longer activate Raf-1 or MAPKs, but retain the ability to bind to other putative Ras targets . Surprisingly, although these eector mutants did not cause signi®cant morphologic transformation when stably expressed in NIH3T3 cells, they promoted a growthtransformed phenotype (growth in low serum, colony formation in soft agar and tumor formation in nude mice) similar to that caused by oncogenic Ras. In contrast to WT Ras, however, these mutants caused a transformed phenotype distinct from that caused by Raf-1, which was similar to that caused by constitutively activated mutants of Rho family proteins. Furthermore, co-expression of these Ras eector domain mutants with activated Raf-1 resulted in potent synergistic transforming activity. The non-Raf eectors that mediate the transforming actions of these two mutants have not been clearly established. However, since Ras(12V, 40C) caused a transformed morphology similar to Rho proteins, retained the ability to activate JNK , and induced membrane ruing in REF52 cells which could be blocked by dominant negative Rac1 (Joneson et al., 1996) , an eector pathway leading to Rac1 may be important for the transforming activity of this mutant protein.
Other studies utilizing these Ras eectors mutants have been conducted recently to investigate how Ras binding to Raf-1 mediates Ras transforming activity, as well as the roles of other candidate Ras eectors in transformation Rodriguez-Viciana et al., 1997; Winkler et al., 1997; Stang et al., 1997) . While these Ras eector mutants aid in identifying and characterizing Ras-mediated signal pathways, they remain incompletely characterized with regard to their ability to bind and activate various Ras eector relative to WT Ras or other activated forms of Ras. Moreover, given dierences in binding, cell type and cell-based assays employed in these studies, caution should be exercised when interpreting the resulting data. Figure 3 Ras subfamily dendrogram. Primary sequences corresponding to Ras subfamily proteins were aligned using ClustalW (Thompson et al., 1994) , a dynamic sequence alignment program. From the resulting multiple sequence alignment, a distance matrix was prepared and used to construct the Ras family dendrogram. The branch lengths in the dendrogram are proportional to the estimated divergence along each branch. With the exception of the mouse homolog, M-Ras, only human sequences are presented
Ras mediates its actions through interaction with multiple eectors
The existence of Raf-independent Ras signaling pathways is further insinuated by the expanding roster of candidate Ras eectors that has emerged over the last several years ( Figure 5 ) (Van Aelst et al., 1994; Marshall, 1996) . Like Raf-1, these structurally and functionally diverse proteins show preferential binding to the active GTP-bound form of Ras and this interaction requires an intact core Ras eector domain. These candidate eector molecules have been identi®ed by a variety of experimental approaches including biochemical methods, yeast two hybrid library screening and yeast functional screening. It is highly likely that additional eectors will be identi®ed. In this section, we summarize our current understanding of the involvement of these candidate Ras eectors in mediating Ras function. We also speculate on the structural requirements for Ras interaction with such a diverse spectrum of functionally divergent targets.
A growing roster of candidate eectors of Ras Putative eectors of Ras have been characterized as binding preferentially to the GTP-bound form of Ras, with binding determinates requiring what has been genetically de®ned as the core Ras eector domain (residues 32 ± 40). This region comprises part of the switch I domain, a region of Ras (residues 30 ± 37) whose conformation diers between GTP-and GDP-bound forms (Tong et al., 1989; Milburn et al., 1990; Krengel et al., 1990) . In addition to the three Raf's, several proteins have been identi®ed with these characteristics (Figure 5 ), but a central goal in the ®eld, is to decide which of these are actually downstream targets of Ras. Critical aims of current studies are to verify whether these candidate Ras eectors actually serve as physiologically relevant eectors of Ras function and to de®ne their precise contribution to Ras signaling and transformation. A demonstration of binding, in either yeast two-hybrid analyses or with puri®ed recombinant proteins in vitro, support the candidacy of a particular protein as a Ras eector. However, while a demonstration of interaction in cells is a key requirement, assessment of binding interactions with full length proteins is also essential. The use of isolated fragments of Raf, that contain RBS1, to assess interaction with Ras, Ras eector mutants or Rasrelated proteins has led to misleading conclusions. For example, it has now been shown that some Ras eector domain mutations which do not impair binding to the isolated Raf-RBS, abrogate interaction with the full length Raf-1 protein (Winkler et al., 1997) . Moreover, the Ras-related protein, TC21, can interact with the isolated Raf-RBS in yeast two-hybrid binding assays, yet failed to bind to and activate full length Raf-1 in vivo (Graham et al., 1996) . The core Ras sequence domain (residues 32 ± 40), containing part of the conformationally sensitive switch I region, may represent a common interaction site for all Ras-GTP binding proteins, and shows complete identity with the equivalent sequences of TC21/R-Ras2, R-Ras and Rap-1A,1B proteins. Sequences that¯ank this core sequence have been shown to be involved in additional binding contacts that promote speci®city and/or activation of downstream eectors. Sequence dierences are seen in the closely related, but biologically-distinct, Rap and R-Ras proteins. Other sequences that may in¯uence eector interactions have been identi®ed in the switch II domain, residues spanning 92 ± 106 and the lipid-modi®ed carboxy terminus Some additional criteria for validating the authenticity of a protein as an eector of Ras are based on evidence for Raf-1 eector function. These include the detection of stable association of Raf-1 with activated Ras in vivo, an increased plasma membrane association of Raf-1 upon Ras activation, and stimulation of Raf-1 kinase activity upon activation of Ras. The use of eector domain mutants that have selectively impaired the ability to activate Raf-1, have aided in assessing the contribution of Raf-1 to Ras transforming activity. Does loss of interaction correlate with loss of transforming activity or loss of a particular Ras function or signaling activity? Finally, high anity binding would be expected of a physiologcially signi®cant eector. However, it should be cautioned that these critiera are not absolute and that bona ®de eectors may not always share these characteristics with Raf.
The best studied Ras GAPs are p120 GAP and neuro®bromin (NF1) (as reviewed in McCormick et al., 1991) . Although p120 GAP and NF1/neuro®bromin clearly function as negative regulators of Ras function (Boguski and McCormick, 1993) , p120 GAP represented the ®rst candidate Ras eector (Adari et al., 1988; CaleÂ s et al., 1988) . Apparent evidence against an eector function for Ras GAPs came from studies of Ras eector domain mutants that impaired p120 or NF1 interactions, yet retained strong focus-forming activity (Marshall and Hettich, 1993) . These observations, together with evidence establishing Raf as a true Ras eector, signaled the demise of the notion that GAPs served as eectors of Ras. However, since Raf-binding de®cient mutants of oncogenic Ras still retained transforming potential , it has become apparent that multiple eectors are required for full Ras function. Therefore, the loss of binding of any one eector alone may not cause a signi®cant alteration to Ras transforming activity. Thus, these eector domain mutagenesis results alone do not rule out an eector role for GAPs. Instead, a signi®cant body of evidence has established intriguing, but incomplete, support for p120 GAP as a Ras eector (Tocque et al., 1997) .
Evidence for p120 GAP eector function was derived from studies that evaluated the activity of NH 2 -terminal fragments of p120 GAP that lack the catalytic GTPase stimulatory domain and Ras-binding sequences. The NH 2 -terminus of p120 GAP contains an SH 3 domain¯anked by two SH 2 domains, a pleckstrin homology (PH) domain, a calcium binding domain, and a site of interaction with phospholipids. In one study, McCormick and colleagues found that a Ras : p120 GAP complex was required for inhibition of muscarinic receptor-activated potassium channel opening, whereas an NH 2 -terminal fragment of p120 GAP could cause this independent of Ras (Yatani et al., 1990; Martin et al., 1992) . In a separate study, it was observed that an antibody directed against the SH 3 domain of p120 GAP blocked Ras-induced germinal vesicle breakdown, but not MAPK activation, when assayed in Xenopus oocytes (Pomerance et al., 1996; Hartwell, 1992) . Similarly, co-expression of a NH 2 -terminal fragment was shown to block oncogenic HRas, but not Raf-1, transforming activity . Moreover, this fragment blocked Ras activation Figure 5 Ras interacts with multiple eectors. In addition to the three Raf serine/threonine kinases (Raf-1, A-Raf and B-Raf), a number of other proteins share properties of a Ras eector, and bind preferentially to active, Ras-GTP. The interaction is dependent on an intact core eector domain. Critical aims of current studies are to verify whether these candidate Ras eectors actually serve as physiologically relevant eectors of Ras function and to de®ne their precise contribution to Ras signaling and transformation of JNK, but not MAPKs (Clark et al., 1997d) . Pawson and colleagues found that overexpression of a p120 GAP NH 2 -terminal fragment altered cell morphology and organization of the actin cytoskeleton (McGlade et al., 1993) . Furthermore, observations that the p120 GAP-associated protein, p190, which is primarily a GAP for RhoA, but is also active on CDC42 and Rac (Settleman et al., 1992) , provides evidence that p120 GAP may serve as an eector that facilitates Ras regulation of Rho protein function. These ®ndings, together with others (reviewed in Tocque et al., 1997) , suggest that p120 GAP may serve dual roles as both a negative regulator of Ras and as a scaolding protein that promotes formation of a Ras-GTP dependent signaling complex with Ras. A current working model proposes that Ras-GTP binding to the COOH-terminal catalytic domain would expose the protein-ligand binding motifs present in the NH 2 -terminus, and the subsequent association of components with the NH 2 -terminus would activate a signaling function. The identi®cation of other p120 GAP-binding proteins in addition to p190 Rho GAP, (e.g., p62
dok , G3BP) provide support for such a scenario (Settleman et al., 1992; Yamanashi and Baltimore, 1997; Ellis et al., 1990; Parker et al., 1996) .
Evidence for NF1 as a Ras eector is less compelling and is based largely on a detection of NF1 function beyond its role as a Ras GTPase stimulator . Like p120 GAP, a signi®cant portion of the 220 kDa NF1 protein is unrelated to its GTPase catalytic function, and consequently, may be involved in an eector function. Clues to such a function are limited, but they suggest an eector function involved in growth suppression rather than promotion. For example, in some studies, no elevation in Ras-GTP was seen in a number of NF1-de®cient tumors (Andersen et al., 1993; Johnson et al., 1993 ), yet introduction of full length NF1 into these cells resulted in severe reductions in growth . These observations suggest that a loss of NF1 function, other than as a Ras GTPase stimulator, contributes to the development of these tumors. In further support of this hypothesis, two separate studies showed that NF1 overexpression inhibited the transformed growth properties of cells that expressed constitutively activated Ras mutants. This would be unexpected if NF1 served simply as a GAP, since the GTPase activity of mutant Ras is not stimulated by NF1. First, Lowy and colleagues showed that overexpression of neuro®bromin drastically reduced (®vefold) viral H-Ras, but not Raf, focus-forming activity . Second, Li and White found that the introduction of full length NF1 into HCT116 colon carcinoma cells, which harbor mutated K-Ras, suppressed soft agar growth in vitro and tumor formation in nude mice (Li and White, 1996) . NF1 overexpression was found to reduce MAPK activation, and introduction of activated Raf could overcome the NF1 suppression (Li and White, 1996) . Thus, these investigators suggested that only modest elevations (2 ± 3-fold) of NF1 expression can block Ras activation of Raf. Third, recent experiments in Drosophila systems have linked neuro®bromin to PKA signaling pathways Izawa et al., 1996) . In summary, the jury is still out with regard to an eector function for Ras GAPs. In the case of both p120 Ras GAP and NF1, a considerable body of indirect evidence suggests that these molecules may play roles in controlling non-Raf/MAPK pathways activated by Ras which may be essential for such neoplastic properties as invasiveness . p120 GAP-or NF1-de®cient mice have been described and both lead to death during embryogenesis (Henkenmeyer et al., 1995; Bollag et al., 1996) . The analysis of whether Ras transforming potential is impaired in ®broblasts derived from the embryos of these animals will provide further assessment of whether Ras GAPs are important eectors of Ras transformation and may identify the signaling pathways that they regulate.
The Ral guanine nucleotide dissociation stimulator (RalGDS) and two closely related proteins (RGL and RGL2/Rlf) represent intriguing candidate eectors of Ras that may link Ras with other Ras-related proteins. Members of this family have been identi®ed repeatedly by yeast two-hybrid library screening searches for candidate eectors of Ras and Ras-related proteins (Rap, R-Ras and TC21/R-Ras2) Hofer et al., 1994; Spaargaren and Bischo, 1994; Wolthuis et al., 1996; Peterson et al., 1996; LoÂ pezBarahona et al., 1996) . RalGDS was identi®ed originally as a CDC25-related protein (yeast RAS GEF) but was found instead to function as a GEF for the two Ras-related proteins RalA and RalB (85% identical to each other; Figures 3 and 4) (Albright et al., 1993) . The COOH-terminal noncatalytic domains of RalGDS, RGL and RGL2/Rlf interact with the eector domain region of Ras in a GTP-dependent manner in vitro and can compete with Raf-1 for binding to the Ras eector domain region in vitro. Ras association with RalGDS has also been observed when overexpressed in COS cells (Kikuchi and Williams, 1996) . Furthermore, the GAP activity of both p120 GAP and NF1-GAP on Ras were competitively inhibited by RalGDS , suggesting that RalGDS, like Raf-1, interacts with Ras in a GTPdependent manner through its eector domain. Although RalGDS and related proteins also bind to Ras-related proteins, transient expression assays in COS cells showed that Ras, but not Rap1A or R-Ras, enhanced the Ral GEF activity of RalGDS (Urano et al., 1996) . This observation underscores an important caution with regard to the interpretation of data showing the ability of a particular protein to bind in vitro. Again, whether full length proteins or fragments are employed in binding analyses and whether binding occurs in vivo needs to be assessed. Moreover, a link between association and stimulation of eector function needs to be established to validate a true interaction.
Evidence that RalGDS may serve as a positive regulator of Ras transformation comes from several independent observations. First, co-expression of isolated Ras-binding domains of RGL and RGL2/Rlf inhibited Ras, but not Raf, transforming activity in NIH3T3 cells (Okazaki et al., 1996; Peterson et al., 1996) . Second, although constitutively activated Ral alone does not cause transformed foci, one study reported that its co-expression enhanced Ras transformation, whereas dominant negative Ral impaired Ras focus-forming activity (Urano et al., 1996) . However, these eects were not dramatic and a second study did not ®nd signi®cant regulation of Ras transforming activity by mutant RalA or RalB proteins . We also found no signi®cant regulation of Ras focus-forming potential by mutants of RalB (Jordan and Der, unpublished observation). Third, co-expression of RalGDS cooperated synergistically with activated Raf-1 to induce transformation of NIH3T3 cells . While RalGDS alone showed no focus-forming activity, we also found that coexpression of RalGDS caused a threefold enhancement of R-Ras, but not Ras or TC21, focus-forming activity (Brtva and Der, unpublished observation). It was not established whether the growth-promoting activity seen with RalGDS was due to its activation of Ral proteins. It is conceivable that RalGDS activation of Ral proteins may in turn lead to either activation of CDC42/Rac or phospholipase D (Jiang et al., 1995) . The identi®cation of a putative RalA eector, RalBP1 that is a novel GAP for CDC42 and Rac, suggests that RalBP1 may regulate these Ras-related GTPases (Cantor et al., 1995) . However, it is also possible that RalGDS may have functions distinct from its Ral GEF activity.
Phosphoinositol 3-kinase (PI3K) is a lipid kinase that phosphorylates phosphoinositides at the 3' position of the inositol ring (Carpenter and Cantley, 1996a) and has also been implicated as a Ras eector ( Figure 5 ). PI3K is composed of a p110 catalytic and a p85 regulator subunit and both are members of a family of related proteins. Multiple isoforms of PI3K can associate with Ras and Ras can activate both wortmanin-sensitive and -insensitive isoforms (Rodriguez-Viciana et al., 1997). Five isoforms of the regulatory subunit and ®ve forms of the catalytic subunit have been identi®ed (as reviewed in Carpenter and Cantley, 1996b ). The catalytic p110 subunits dier in their substrate speci®city and regulation. A novel PI3K isoform has recently been identi®ed (p110d), which unlike p110a, does not phosphorylate p85 but instead harbors an intrinsic autophosphorylation capacity. The p110d cataytic domain contains unique potential protein-protein interaction modules such as a proline-rich region and a basic-region leucine-zipper like domain (Vanhaesebroeck et al., 1997) . Additionally, another p110 isoform designated p100O was also identi®ed during a yeast two-hybrid library screen for Ras-interacting proteins (Vojtek et al., 1993) .
Recombinant p110 (a-and b-) showed high anity interaction with the GTP-bound form of recombinant Ras through the Ras eector domain (RodriguezViciana et al., 1994 (RodriguezViciana et al., , 1996 . In intact cells, there is evidence that Ras can stimulate PI3K activity and is required for its optimal activation in response to growth factors (Kodaki et al., 1994; RodriguezViciana et al., 1994) . Furthermore, dominant negative Ras inhibited platelet-derived growth factor (PDGF) activation of PI3K. In addition, introduction of activated Ras, but not Raf, into COS cells resulted in a signi®cant induction of inositol phosphates demonstrating the convergence of Raf and PI3K pathways at the level of Ras. Taken together, these observations suggest strongly the involvement of PI3K as a downstream eector of Ras function (RodriguezViciana et al., 1994).
Although the eect of Ras on PI3K activity in vitro is modest (*twofold) using bacterially expressed recombinant Ras, it is possible that like Raf-1, PI3K activation requires posttranslational modi®cation of Ras and/or other factors to achieve full stimulation of PI3K activity (Kodaki et al., 1994) . In fact, is has been recently shown that Ras-GTP can activate the lipid kinase activity of PI3K directly in vitro and that this eect is synergistic with tyrosine phosphopeptide binding to p85 (Rodriguez-Viciana et al., 1996) . The site of interaction of Ras with PI3K resides between residues 133 ± 314 on the catalytic p110 subunit, with lysine residue 227 being essential for the interaction (Rodriguez-Viciana et al., 1996) . This is a region immediately carboxy terminal to the site of interaction between p110 and the p85 regulatory subunit, suggesting a model where PI3K is regulated through at least two domains in its amino-terminal regulatory domain, one from tyrosine phosphoproteins through its SH 2 binding site and Ras-GTP. The closely related members for the Ras family Rap1A/B, R-Ras and TC21 all interact with PI3K, although Rap2 and Ral did not. However, with the exception of R-Ras it is not yet clear whether binding to these Ras-related GTPases to PI3K leads to its activation in vivo .
A number of signaling molecules have been implicated downstream of PI3K, including Rac, p70S6 kinase, PKB/AKT, and novel and atypical isoforms of protein kinase C (Carpenter and Cantley, 1996b) . One of the downstream targets of activated PI3K, protein kinase B (PKB; also Akt), has received a great deal of attention recently (Franke et al., 1995; Klippel et al., 1996; Marte et al., 1997) , as a series of studies have identi®ed a role for PKB in cell survival (as reviewed in . A recent study using Ras eector domain mutants implicated the PI3K/PKB in oncogenic Ras suppression of Mycinduced apoptosis in Rat-1 ®broblasts, whereas Ras activation of the Raf4MEK4MAPK pathway was found to promote the Myc apoptotic response (Kaumann-Zeh et al., 1997) . Since oncogenic Ras also potentiated the apoptotic response, the Rafmediated pathway may be dominant over the PI3K pathway. In addition, R-Ras has been shown to bind to and activate PI3K , and this interaction leads to PI3K-PKB/Akt pathway activation, but not the Raf-MAP kinase pathway . These results indicate the existence of a Ras signaling cascade parallel to the Raf/MEK/MAPK pathway where Ras binds and activates PI3K, causing activation of PKB. A direct mechanism of PKB activation by PI3K that involves the binding of PtdIns-3,4,5,-P 3 to the PKB PH domains has been described recently Klippel et al., 1997) . Since the PI3K products, PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 , can regulate the activities of a wide variety of proteins, including PKC isoforms and proteins that regulate the actin organization (e.g. pro®lin), the consequences of PI3K activation are likely to be beyond AKT and will be complex.
On the other hand, several observations implicated PI3K as an upstream activator of Ras function. First, phosphorylation of PDGFR at sites that are involved in p85 binding is required for the activation of Ras by PDGF (Fantl et al., 1992) . Second, an activated form of p110 caused a small elevation in the level of activated Ras-GTP in vivo . One possible resolution to these apparently contradictory roles of PI3K is that, depending on the speci®c extracellular stimulus or cell type, PI3K isoforms may act as either an upstream activator or a downstream mediator of Ras function.
Another candidate eector of Ras is the mitogenactivated protein kinase kinase kinase 1 (MEKK1), a serine-threonine kinase that is an upstream activator of SEK (a MAPKK), which in turn activates JNK/ SAPK ( Figure 5 ) (Lange-Carter et al., 1993; Yan et al., 1994) . MEKK1 can be activated in response to a variety of extracellular stimuli, ultraviolet radiation, as well as activated Ras. Evidence for its role as a Ras eector comes from observations that MEKK1 bound directly to GST-Ras(12V) in a GTP-dependent manner via its COOH-terminal kinase domain in vitro (Russell et al., 1995) . This binding was blocked by a Ras eector peptide. Whether MEKK1 is a true Ras eector remains to be critically tested. Since overexpression of MEKK1 causes apoptosis Cardone et al., 1997) , it seems unlikely that it would be an important positive eector for Ras transforming activity. MEKK1 has also been shown to bind to GTP-complexed Cdc42 and Rac1 in vitro and kinase-dead MEKK1 can block Cdc42/Rac activation of JNK (Fanger et al., 1997) . Thus, MEKK1 may serve as eectors of Cdc42 and Rac as well. Finally, MEKK1 showed a nuclear location and an association with vesicular-like structures in the cytoplasm (Fanger et al., 1997) . However, the relevance of this subcellular location and the functional interaction with plasma membrane associated Ras proteins is not clear. AF6/Rsb1 is yet another candidate Ras eector that was identi®ed by yeast two-hybrid library screening for Ras-binding proteins and by anity chromatography puri®cation of Ras-GTP-binding proteins ( Figure 5 ) (Van Aelst et al., 1994; Kuriyama et al., 1996) . AF-6 shows a high degree of sequence similarity to Drosophila Canoe, which is assumed to function in signaling pathways downstream from the Notch receptor, acting as a regulator of cellular differentiation (Hunter, 1997) . The p180 AF-6 protein was also identi®ed independently as one of up to ten fusion partners of the MLL protein associated with chromosome translocation events in human leukemias (Prasad et al., 1993) . The MLL/AF-6 chimeric protein is the gene product of a reciprocal translocation t(6;11)(q27;q23) associated with a subset of human acute lymphoblastic leukemias (Prasad et al., 1993; Tanabe et al., 1996; Taki et al., 1996) . Transcripts for the reciprocal AF6/MLL fusion have not been detected (Tanabe et al., 1996; Taki et al., 1996) . Interestingly, all MLL/AF-6 fusion proteins contain the identical AF-6 residues, 36 ± 1612. In vitro analyses showed that the NH 2 -terminal domains of AF6 and Canoe interacted speci®cally with GTP-bound form of Ras and this interaction interferes the binding of Ras with Raf (Kuriyama et al., 1996) . AF-6 appears to be expressed in a variety of tissues. Presently, a function for AF-6 has not been determined. However, limited sequence homology was observed between AF-6 and proteins that may be involved in signal transduction at special cell-cell junctions.
Yeast studies looking for genes that interfere with Ras function identi®ed the Ras interaction/interference gene 1 (Rin1) that suppressed activated RAS2-induced cyclic AMP activation (Han and Colicelli, 1995) . This interference is at the level of RAS2, since Rin1 cannot suppress the activity of components downstream of RAS2 in the adenylyl cyclase pathway. Additionally, in vitro binding and yeast two hybrid analysis demonstrated that Rin1 directly interacted with RAS2 as well as the mammalian H-Ras. This interaction was GTPdependent and required an intact Ras eector domain. Furthermore, Rin1 competed with Raf-1 in binding to Ras in vitro (Han and Colicelli, 1995) . A 434 amino acid region of Rin has been shown to be required for ecient Ras binding . Finally, the demonstration that Ras and Rin1 can form a stable complex in vivo provides strong evidence that Rin1 is a physiologically relevant eector of Ras . Although overexpression of Rin1 alone in NIH3T3 cells showed no growth-promoting activity, we have observed that co-expression of Rin1 with activated R-Ras showed a synergistic enhancement of focus-forming activity (Brtva, Colicelli and Der, unpublished) . Thus, Rin1 may be involved in positive growth regulation.
Recent evidence suggests a possible role of Rin1 in linking Abl tyrosine kinase function with Ras. First, the Abl tyrosine kinase was found to bind Rin1 in vitro and served as a substrate for its kinase activity . However, no association between Abl and Rin1 was detected in vivo. Second, co-expression of Rin1 greatly potentiated the transforming activity of the chimeric BCR-Abl fusion protein . BCR-Abl is implicated in the development of Philadelphia Chromosome-positive human leukemias. This interaction required tyrosine phosphorylation of Rin1 to mediate its interaction with the Abl SH 2 and SH 3 domains. Stable complex formation between Rin1 and BCR-Abl was seen. Whether Rin1 can complex simultaneously with BCR-Abl and Ras is not known. Moreover, like the cysteine-rich domain of Raf-1 (Clark et al., 1997b) , a domain of Rin1 that binds Ras also binds 14-3-3 proteins . Thus, it appears that Rin1 can interact with multiple signaling molecules and may possess functions distinct from those of Ras.
The zeta isoform of protein kinase C (PKCB) has also been implicated as a Ras eector. First, PKCB was required for Ras-induced maturation in Xenopus oocytes (Dominguez et al., 1992) and serum-stimulated mitogenic signaling in mammalian cells (Berra et al., 1993) . Second, the regulatory NH 2 -terminal fragment of PKCB showed preferential binding to Ras-GTP in vitro and a peptide corresponding to Ras residues 17 ± 44 blocked this interaction. (Diaz-Meco et al., 1994) . Furthermore, PDGF stimulation promoted PKCB association with Ras in vivo. Finally, dominant negative H-Ras(17N) blocked PDGF-stimulated activation of PKCB. Taken together, these observations suggest that PKCB may serve as a positive regulator of Ras growth stimulation.
In summary, a growing family of candidate Ras eectors has emerged. However, to date, the precise roles, if any, of these Ras-GTP binding proteins in mediating Ras downstream signal transduction and transformation remains to be established. It is likely that some of these proteins may be involved in mediating normal Ras function while others may be critical mediators of Ras transforming activity. A subset of these proteins may actually be negative regulators of Ras function by preventing the interaction of Ras with bona ®de Ras eectors. Moreover, it is possible that distinct mammalian Ras (H-Ras, K-Ras, N-Ras) proteins and/or Ras mutants (for example, positions 12,13,61) may dier in their ability to recognize and activate downstream targets, resulting in dierential signaling . For example, gene targeting studies indicate an essential role for Kras, but not H-or N-Ras, for normal development in mice (Koera et al., 1997; Johnson et al., 1997) . This data, taken together with earlier observations that KRas-4B possesses distinct carboxy terminus modifications (James et al., 1995) and the speci®c association of KRas4B with smg-GDP dissociation stimulator (GEF) (Mizuno et al., 1991) , suggests that K-Ras may have speci®c functions in signal transduction not shared by other family members. This might explain why most Ras mutants in human tumors contain K-Ras mutations at position 12 (Barbacid, 1987; Bos, 1989; . Finally, it is likely that a portion of these candidate eectors may not serve as true Ras eectors, but rather eectors for one or more of the closely related proteins such as TC21, R-Ras or Rap. Analysis of the role of these proteins in the function of Ras and Ras-related proteins is the focus of ongoing investigations in many laboratories.
Structural requirements for Ras : eector interactions The current roster of candidate Ras eectors is comprised of a very diverse collection of structurally and functionally distinct proteins. The conformation of Ras-GTP diers from Ras-GDP in two distinct regions, designated switch I (Ras residues 30 ± 37) and switch II (Ras residues 59 ± 76) (Tong et al., 1989; Milburn et al., 1990; Krengel et al., 1990) . Since switch I overlaps with the Ras eector domain sequences, a common feature of candidate Ras eectors is the loss of binding to Ras-GTP due to mutations in the core Ras eector domain (32 ± 40). Thus, it is not surprising that this region is important for eector interaction and may represent a shared binding region important for all Ras eectors. A Ras-GTP binding motif has recently-been proposed based on limited sequence and predicted structural similarity between RalGDS and AF-6, and designated the RA domain (Ponting and Benjamin, 1996) . The RA domain is predicted in a number of candidate Ras eectors (RalGDS, AF-6/ Canoe and Rin-1), but not in others (Ras GAPs, PI3K, MEKK1). Although the alignment and hypothesis is intriguing, Kalhammer et al. (1997) failed to detect direct binding between the putative RA domain in Myr 5 and Ras, suggesting that the identifed RA domain does not reliably predict Ras-binding domains.
The speculation that some candidate eectors share a common tertiary structure, despite the distinct primary sequences seen among some Ras-GTP binding proteins, is intriguing. However, the ability of speci®c amino acid mutations to cause selective impairment of only a subset of Ras-GTP binding partners suggests that the binding determinants will be distinct. The recent determination of the structures of three Ras-GTP binding domains support both possibilities.
GAPs for Ras, as well as Ras-related proteins have been implicated as possible eectors. The X-ray structure of the p120 Ras GAP catalytic domain (Ras GAP-CAT) has recently been solved (Schezek et al., 1996) and shown to have an all-helical fold that is distinct from GAP domains of two RhoGAPs (p85 and p50 RhoGAP) (Musacchio et al., 1996; Barrett et al., 1997) and Ga i1 -RGS (Tesmer et al., 1997) . Hence, even GAP domains from Ras-related proteins and heterotrimer G-proteins with similar functional properties show distinct tertiary folds. The overall topology of Ras GAP-CAT, in turn, is quite distinct from that of Raf-RBS (Emerson et al., 1995; Nassar et al., 1995) , in that Raf-RBS possesses a mixed a/b fold similar to that of ubiquitin. Interestingly, despite the low level of sequence homology between Raf-RBS and the Ras interaction domain of RalGDS (RalGDS-RID), Raf-RBS has been shown to have a similar tertiary fold to RalGDS-RID (Huang et al., 1997; Geyer et al., 1997) . In fact, NMR chemical shift mapping studies of RalGDS-RID in a complex with Ras, indicate an interaction similar to the intermolecular beta-sheet observed for the complex between Ras and Raf-RBS (Geyer et al., 1997) . Furthermore, mutagenesis studies indicate that several residues in RalGDS-RID that mediate binding to Ras are located at sites that correpond to those important for binding by Raf-RBS (Huang et al., 1997; Geyer et al., 1997) . Hence, it is tempting to speculate, given the structural and mutagenesis data, that the RalGDS-Ras complex will be similar to the Ras-Raf complex, and may provide a common structural basis for interaction with a subset of Ras eectors. Moreover, using N-and C-terminal deletions of Rlf, the minimal eective Ras binding domain of the RalGDS-related protein, RLF, was determined to encompass residues 657 ± 778 (O'Gara et al., 1997). The secondary structure of this domain was also predicted to be similar to the ubiquitin fold previously determined for Raf-RBS. Alignment of Rlf-RBS with Raf-RBS and mutagenesis of K687 in Rlf-RBS suggest conservation of amino acids in Raf-1 essential for Ras binding to Rlf (O'Gara et al., 1997) . Thus, it appears, that both a common structural manifold and conservation of critical complementary Ras eector interactions may represent shared Rasbinding properties among a subset of Ras eectors. It will be interesting to see whether other candidate Ras eectors share a similar fold.
A characteristic feature of the GTP-bound form of Ras is that the switch regions are dynamic and undergo interconversion between two or more conformers. This conformational polymorphism has been proposed to mediate recognition and interaction with regulators and downstream targets of Ras, such as Raf-1 and Ras GAPs (Ito et al., 1997; Geyer et al., 1996) . Although a common feature of Ras targets, are binding determinants present in the GTP-bound form of the Ras eector domain, it is possible that each target preferentially recognizes and binds a distinct conformer presented by the polysteric binding interface of Ras. Moreover, structural and mechanistic studies of the GAP-stimulated GTP hydrolysis of Ras indicate that RasGAPs supply a catalytic residue, termed the arginine ®nger, into the active site of Ras to neutralize developing charges in the transition state. Moreover, it has been proposed, that GAP proteins also facilitate GTP hydrolysis by binding and reducing the mobility within the GTPase catalytic center Ahmadian et al., 1997; Wittinghofer et al., 1997) . Therefore, a number of factors appear to be involved in target/regulator interactions with Ras including: the structural manifold, presence of both common and distinct complementary binding interactions, and conformational mobility.
One additional complexity to this issue is the likelihood that the various Ras-binding proteins are likely to interact with distinct and multiple sequences in Ras (Figure 4) . Thus, the original de®nition of the Ras eector domain (Sigal et al., 1986) is clearly an over simpli®cation. The crystal structure of Rap bound to the slowly-hydrolyzable GTP analog, GppNHp, demonstrated that Raf-RBS (residues 51 ± 131) contacts Rap primarily though residues 30 ± 41, in and around switch I region (Nassar et al., 1995) . However, not all the genetic data can be rationalized from these critical contacts between Ras/Rap and Raf-1. Mutation of residues¯anking the core eector region (spanning Ras residues 26 ± 45) can also in¯uence Ras transforming activity and Ras interaction with candidate eectors (Shirouzu et al., 1994; Fujita-Yoshigaki et al., 1995) . In particular, Ras variants containing mutations at 26 or 45 which are close to the interface but do not make contact with RBS, retain high anity binding to RBS, but cannot activate Raf-1. These data suggest that other elements of Ras and/or Raf-1 are involved in interactions important for activation, consistent with recent data that Ras regions¯anking residues 31 ± 41 (particularly 26 and 45) are involved in additional contacts with Raf-1 via the Raf-CRD domain . Interestingly, the binding contacts between unprocessed and processed forms of Ras and the cysteine-rich domain do not show a strong preference for either Ras-GTP or Ras-GDP, consistent with binding interactions outside the switch domains Drugan et al., 1996) . In Raf-1, the initial contact appears to be mediated by Raf-RBS and Ras-GTP, which is necessary for Raf-1 translocation, whereas the cysteine-rich domain of Raf-1 appears to be required for full activation of Raf-1 activity by Ras. It will be interesting to see if other Ras targets possess similar modes of recognition and activation, where membrane localization is mediated by the Ras-GTP binding to the switch I domain, and target activation by other regions of Ras.
Similarly, mutagenesis of switch II residues also support their importance in interaction with at least some candidate eectors (Moodie et al., 1995; Hwang et al., 1996; Drugan et al., 1996) . For example, Y64G/ S65G or Y64G/Y71G double mutants of H-Ras were impaired in complex formation with NF1 or PI3K (Moodie et al., 1995) . Furthermore, mutation of residues 60 or 64 also perturbed Ras interaction with Raf-1 (Drugan et al., 1996) . However, NMR structural analysis of these Ras variants suggest that the mutations produce structural changes remote from the site of mutation and thus these residues may not be directly involved in contacts with Raf-1 (Sharon Campbell, unpublished observations). The Q61L oncogenic mutation increases anity for both GAPs (Vogel et al., 1988) , consistent with the recently determined structure of Ras complexed with the catalytic domain of p120 Ras-GAP. Interestingly, whereas only WT Ras-GTP, binds to Raf-1 with high anity leading to Raf-1 activation, both Q61L Ras-GDP and Q61L Ras-GTP bind Raf-1 with reasonable anity and can lead to its activation (Moodie et al., 1995) . A possible explanation for these observations, is that the mutation alters another a region of the protein whose conformation is not GTP-dependent such that it increases binding anity to Raf-1 in a GTPindependent manner. It is intriguing that the corresponding mutation in Rac restores binding and activation of NADPH oxidase interactions when placed in the context of Rac eector domain mutations (Dorseuil et al., 1996) and lends further support for this hypothesis. So, the unusual nature of this mutation may be a conserved feature of at least of subset of Ras-related GTPases. Whether switch II is important for interaction with all Ras eectors is presently not known. Mutation of yet other residues (e.g., residues 92 or 106) suggests a third region of contact between Ras and Ras GAPs and possibly other eectors (Morcos et al., 1996; Parrini et al., 1996; Yoder-Hill et al., 1995) . The three dimensional structure of Ras GDP bound to GAP-CAT has recently been solved and consistent with mutational studies, residues of the phosphate binding loop (residues 10 to 16), switch regions I (30 to 37) and II (59 to 76) and possibly helix a3 (87 to 98) on Ras participate in binding interactions.
Furthermore, COOH-terminal farnesylation of Ras appears to be important for high anity interaction with Raf, suggesting that the Ras COOH-terminus may also be involved in eector interaction Luo et al., 1997) . The presence of the farnesyl group also appears to be important for Ras2 activation of adenylate cyclase (Kuroda et al., 1993) .
Although it is clear that Ras sequences important for eector interactions are complex and involve multiple distinct sequences, the core eector region (32 ± 40) appears to be an essential element for all eector interactions. Several members of the Ras branch of the Ras superfamily share complete identity with Ras in this core eector domain, including the Rap proteins, R-Ras and TC21 (Figure 4 ). Whether these Ras-related proteins share eector utilization with Ras, or whether some Ras binding proteins are really eectors for Ras-related proteins remains incompletely understood. Hence, studies of Rasrelated proteins may shed some light on the Ras sequences and eectors important for Ras transforming activity.
Although several members of the Ras branch of the Ras superfamily share complete identity with Ras residues 32 ± 40 and can also bind to many Ras-GTP binding proteins, they exhibit distinct biochemical and biological properties. For example, although activated forms of TC21 cause the same transforming and dierentiating actions as Ras, TC21 fails to bind to and activate Raf kinases (Graham et al., 1996) . We have found that, like Ras, TC21 can cause growth transformation of NIH3T3 and other cells (Graham et al., 1994) , promote the dierentiation of PC12 pheochromocytoma cells, and block serum starvationinduced dierentiation of C2 skeletal myoblasts (Graham et al., in preparation) . Thus, it will be interesting to determine if TC21 utilizes any of the candidate eectors for Ras to mediate these activities.
Our yeast two-hybrid binding analyses have determined that TC21 can bind some (e.g., RalGDS, AF6), but not all (Rin1 or Raf-1) known Ras binding proteins (Graham et al., in preparation) . These properties of TC21 emphasize the critical role of sequences outside the core eector region in specifying not only eector binding but also eector activation, and further support the importance of Raf-independent pathways in mediating transformation.
Even though activated mutants of R-Ras can cause transformation of NIH3T3 cells, they clearly dier from Ras and TC21 in biological activity. For example, R-Ras transformed NIH3T3 cells lack the strong morphologic transformation seen with Ras transformed cells. Furthermore, whereas activated Ras or TC21 can overcome the loss of endogenous Ras function caused by the Ras(17N) dominant negative, activated R-Ras apparently lacks the Ras functions required to maintain normal cell proliferation (Hu et al., 1997) . R-Ras may regulate cellular processes (apoptosis, integrin-mediated cellular adhesion) distinct from Ras Hu et al., 1997; Marte et al., 1997) . Like TC21, R-Ras does not demonstrate high anity binding to Raf or promote kinase activation. However, like Ras, R-Ras can activate a PI3K/PKB pathway . Nevertheless, since activated PI3K or PKB does not share the same transforming potential as R-Ras, R-Ras must utilize other eectors as well.
Although Rap1A/Krev-1 can interact with most Ras binding proteins, such as to Raf-1, GAPs and RalGDS Frech et al., 1990; Hata et al., 1990; Kikuchi et al., 1994; Hofer et al., 1994; Wolthuis et al., 1996; Spaargaren and Bischo, 1994; Peterson et al., 1996; LoÂ pez-Barahona et al., 1996) , activated forms of Rap1A fail to cause transformation. Instead, Rap1A has been shown to antagonize Ras transforming activity. This antagonism has been attributed to the ability of Rap1A to form nonproductive complexes with key Ras eectors important for Ras transforming activity. This may occur because Rap1A may bind, but fail to activate some Ras eectors such as Raf-1 (Kitayama et al., 1989 (Kitayama et al., , 1990 . Alternatively, since Rap1A is located in the endoplasmic reticulum and Golgi, it may sequester Ras eectors in a subcellular location that prevents their complete activation to or from functional signaling complexes (Beranger et al., 1991; Sato et al., 1994; Cook et al., 1993) . The ability of Rap1A to block Ras activation of ERKs suggests that Raf-1 is one of the Ras eectors targeted by this Ras antagonist. However, since it has been described that activated Rap can promote the proliferation of Swiss 3T3 cells, Rap1A may use Ras eectors, or Rapspeci®c eectors, to mediate functions beyond antagonizing Ras (Yoshida et al., 1992; .
Another Ras subfamily protein, designated Rheb, for Ras homolog enriched in brain, has been described recently (Yamagata et al., 1994) . The observation that Rheb retains conservation with Ras in six out of nine residues in the core eector domain suggests that Rheb may share common eector interactions with Ras ( Figure 4 ). Similar to Ras, Rheb also encodes a CAAX box that is farnesylated and sensitive to farnesyltransferase inhibition (Clark et al., 1997c) . Our analyses of Rheb function suggest that Rheb shares greater functional relationship with Rap proteins, although the previously noted sequence homology with Rap1A is not observed in our sequence alignment (Yamagata et al., 1994) . For example, constitutively activated mutants of Rheb failed to cause growth or morphologic transformation of NIH3T3 cells. Rheb has also been shown to interact with Raf-1 (Clark et al., 1997c) . Hence, the lack of transforming potential exhibited by Rheb may result from antagonizing Ras signaling and transformation possibly by formation of a nonproductive complex with Raf and other Ras eectors. Recent ®ndings that lend support for this hypothesis indicate that Rheb binds but does not activate Raf-1, eectively inhibiting the activation of Raf-1 by Ras. Intriguingly, although Rap proteins do not activate Raf-1, they will stimulate the kinase activity of B-Raf (Vossler et al., 1997) . We have recently found that activated forms of Rheb may exhibit similar properties (Geo Clark, unpublished observations).
Recently, additional small GTPases have been identi®ed that also share strong, but incomplete, identity with the core Ras eector domain and anking sequences. Using a PCR-based approach with degenerate primers corresponding to conserved regions in Ras and employing as template, mouse retinal cDNA, three novel small GTPases were cloned (Lee et al., 1996) . One of the two GTPases, named Rin for Ras-like protein expressed in neurons, binds calmodulin in a Ca 2+ -dependent manner, suggesting it may be involved in mediating calcium-dependent signaling within neurons (Lee et al., 1996) . Rit, on the other hand, stands for Ras-like protein expressed in many tissues. Like Rin, Rit does not contain a sequence for prenylation or palmitoylation but nontheless, both appear to be plasma membrane localized. Both proteins contain a similar core effector domain to Ras but contain histidine instead of tyrosine at position 32 and an alanine instead of serine at position 39 (Figure 4) . Finally, an unpublished Rasrelated protein, designated M-Ras, has also been identi®ed. Whether Rit, Rin or M-Ras share common eectors with Ras, and whether constitutively activated mutants will cause cellular transformation is presently not known. The signaling pathways mediated by these novel GTPases are currently under investigation.
Increasing complexity of Ras signal transduction: a boon or a bust for drug discovery and the development of antiRas drugs for cancer treatment?
A promising approach for targeting Ras for cancer treatment involves the use of farnesyltransferase inhibitors (FTIs) . FTIs block Ras function by preventing its posttranslational modi®cation by the farnesyl isoprenoid. Although current evidence support the potential use of FTIs for cancer treatment, some concerns exist since FTIs block all Ras function. Thus, since Ras protein function is believed to be central to so many cellular processes, targeting only a subset of Ras functions by downstream intervention may provide signi®cant advantages. Therefore, another approach for targeting Ras protein function involves the development of inhibitors that prevent activated Ras from relaying its downstream signal by interfering at dierent points in its signaling cascades (Gibbs and Oli, 1994; Der et al., 1996) .
For example, components of the Raf4MEK4MAPK cascade has been targeted by ongoing eorts at a number of pharmaceutical companies. However, because of the revelations indicating the complexity of Ras signaling pathways required for transformation are complex, such eorts may be premature. Instead, it may be better to wait until full appreciation of the involvement of Ras in the signaling circuitry that regulates cell growth and dierentiation can be achieved.
While the unknown complexities of Ras signaling pose serious concerns with regard to identifying the most appropriate and key downstream components for intervention, there is also evidence that intervention at any number of points may be promising. Ras transformation of rodent ®broblasts can be antagonized by dominant negative mutants of Raf, MEK or MAPK (Kolch et al., 1991; Schaap et al., 1993; Cowley et al., 1994; Westwick et al., 1994; Qiu et al., 1995a; Khosravi-Far et al., 1995) , by dominant negative Rho family proteins (Qiu et al., 1995a,b; Prendergast et al., 1995) , by blocking the action of speci®c transcription factors (Myc, Fos, Jun, Ets and NFkB) (Sklar et al., 1991; Granger-Schnarr et al., 1992; Langer et al., 1992; Clark et al., 1997d; Finco et al., 1997; Mayo et al., 1997) . These observations provoke an apparent paradox. If mutants of Ras that fail to activate the Raf4MEK4MAPK pathway can still cause transformation, then why does blocking this kinase cascade still result in potent inhibition of Ras transformation? One possible resolution to this paradox is that full Ras transformation requires the action of multiple pathways. However, the impairment of any one of several key pathways alone will signi®cantly impair Ras transforming function, and consequently, may have a signi®cant impact on reversing the malignant and invasive growth properties of cancer cells. Thus, while many components of Ras signaling remain to be identi®ed, and their precise role in Ras transformation established, we may already have sucient knowledge to target Ras signaling to initiate these drug discovery eorts.
Future directions
Despite a rapid and impressive accumulation of information regarding Ras eector utilization, we are at a point in discovery where there are more questions than answers. What is clear is that Ras does not simply activate Raf. Presently, Raf remains the major eector of Ras function. If Raf serves as a prototypic Ras eector, Ras binding and eector activation are likely to be mediated through multiple interaction sites, via a multistep activation process requiring complex formation with other factors. Will other eectors prove to be equally important? Of those that have been identi®ed, which Ras-binding partners will be legitimate Ras targets? Clearly, Raf and PI3K appear to be important ones. If other eectors are validated, de®ning their contribution to Ras function will be important. Some, but not all, are likely to be important mediators of Ras transformation. Are more eectors yet to be found? This seems very likely, including tissue-speci®c eectors.
Several questions relating to the regulation of Ras function via eector utilization remain. If Raf and other eectors lack GAP function, how is the interaction terminated? Most are ubiquitously expressed. Consequently, how is speci®c eector utilization regulated? Does the cell regulate eector utilization by controlling levels of expression? Will Ras activation by dierent Ras GEFs cause dierent subcellular locations that then promote distinct eector utilization? Will the formation of distinct signaling complexes, with dierent combinations of eectors, dictate the function of each eector? Will cell type dierences in eector utilization be seen? Will each eector mediate the distinct biological properties of Ras (growth versus dierentiation versus apoptosis). For example, recent studies have implicated speci®c Rho family proteins as Raf-independent mediators of Ras transformation (Rac, Rho and CDC42). Which eector(s) connect Ras to Rho family proteins will be important to determine. Will common eector utilization provide cross talk between dierent Ras-related proteins? Will distinct eector utilization be seen for the four Ras proteins? Will one eector pathway be a key target for drug discovery or will dierent eector pathways be important in dierent tumors?
